JP2023525991A5 - - Google Patents

Info

Publication number
JP2023525991A5
JP2023525991A5 JP2022567223A JP2022567223A JP2023525991A5 JP 2023525991 A5 JP2023525991 A5 JP 2023525991A5 JP 2022567223 A JP2022567223 A JP 2022567223A JP 2022567223 A JP2022567223 A JP 2022567223A JP 2023525991 A5 JP2023525991 A5 JP 2023525991A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable region
polypeptide sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022567223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525991A (ja
JP7821121B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/031055 external-priority patent/WO2021226321A2/en
Publication of JP2023525991A publication Critical patent/JP2023525991A/ja
Publication of JP2023525991A5 publication Critical patent/JP2023525991A5/ja
Application granted granted Critical
Publication of JP7821121B2 publication Critical patent/JP7821121B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022567223A 2020-05-07 2021-05-06 抗腫瘍関連抗原抗体及びその使用 Active JP7821121B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063021215P 2020-05-07 2020-05-07
US63/021,215 2020-05-07
US202062706131P 2020-08-03 2020-08-03
US62/706,131 2020-08-03
US202063198420P 2020-10-16 2020-10-16
US63/198,420 2020-10-16
US202063131394P 2020-12-29 2020-12-29
US63/131,394 2020-12-29
PCT/US2021/031055 WO2021226321A2 (en) 2020-05-07 2021-05-06 Anti-tumor associated antigen antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2023525991A JP2023525991A (ja) 2023-06-20
JP2023525991A5 true JP2023525991A5 (cg-RX-API-DMAC7.html) 2024-05-20
JP7821121B2 JP7821121B2 (ja) 2026-02-26

Family

ID=78468388

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567223A Active JP7821121B2 (ja) 2020-05-07 2021-05-06 抗腫瘍関連抗原抗体及びその使用

Country Status (11)

Country Link
US (1) US20230220107A1 (cg-RX-API-DMAC7.html)
EP (1) EP4146702A4 (cg-RX-API-DMAC7.html)
JP (1) JP7821121B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230007452A (cg-RX-API-DMAC7.html)
CN (1) CN115515981A (cg-RX-API-DMAC7.html)
AU (1) AU2021267893A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022020716A2 (cg-RX-API-DMAC7.html)
CA (1) CA3173176A1 (cg-RX-API-DMAC7.html)
IL (1) IL297955A (cg-RX-API-DMAC7.html)
MX (1) MX2022013920A (cg-RX-API-DMAC7.html)
WO (1) WO2021226321A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
KR20240013094A (ko) 2021-03-17 2024-01-30 마이얼로이드 테라퓨틱스, 인크. 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법
EP4605425A1 (en) * 2022-10-18 2025-08-27 Zymeworks BC Inc. Antibody-drug conjugates targeting glypican-3 and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化n端ペプチドに対する抗体
AU2008275985B2 (en) * 2007-07-17 2013-09-19 E. R. Squibb & Sons, L.L.C. Monoclonal antibodies against Glypican-3
US9206257B2 (en) * 2011-04-19 2015-12-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
JP2017522861A (ja) * 2014-05-22 2017-08-17 ジェネンテック, インコーポレイテッド 抗gpc3抗体及びイムノコンジュゲート
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TW201713700A (zh) * 2015-05-27 2017-04-16 台灣泰福生技股份有限公司 抗glypican-3抗體及其用於診斷及治療癌症之用途
EP3431102A4 (en) * 2016-03-14 2019-09-25 Chugai Seiyaku Kabushiki Kaisha CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY
CN109153719B (zh) * 2016-03-15 2022-12-30 中外制药株式会社 使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法
WO2017162587A1 (en) * 2016-03-22 2017-09-28 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific molecules
CN118421557A (zh) * 2016-05-12 2024-08-02 阿迪塞特治疗公司 选择性扩增γδT细胞群的方法及其组合物
EP3551220B1 (en) * 2016-12-07 2025-01-29 Genentech, Inc. Anti-tau antibodies and methods of use
EP3615574B1 (en) * 2017-04-26 2026-06-24 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
JP7382922B2 (ja) * 2017-09-20 2023-11-17 中外製薬株式会社 Pd-1系結合アンタゴニストおよびgpc3標的化剤を使用する併用療法のための投与レジメン
AR114112A1 (es) * 2018-02-15 2020-07-22 Seattle Genetics Inc Anticuerpos de glipicano 3 y conjugados de los mismos
CN111040036B (zh) * 2018-10-12 2023-10-20 上海卡智生物技术有限公司 抗gpc3单克隆抗体、由其修饰的免疫效应细胞及其应用

Similar Documents

Publication Publication Date Title
JP2021514664A5 (cg-RX-API-DMAC7.html)
CN112867507B (zh) 新型抗sirpa抗体
IL276830B1 (en) Anti-claudin 18.2 antibodies and their uses
CN102209730B (zh) 抗cxcr4抗体及其用于治疗癌症的用途
JP7066953B2 (ja) 二重特異性抗体およびその応用
TWI414532B (zh) 抗第1型類胰島素生長因子接受器之抗體及其之使用
JP2020510422A5 (cg-RX-API-DMAC7.html)
JP2024531409A5 (cg-RX-API-DMAC7.html)
CN102939306B (zh) 用于治疗癌症的人源化抗cxcr4抗体
IL310938A (en) Anti-CCR8 antibodies and their uses
JP2022527173A5 (cg-RX-API-DMAC7.html)
JP2022526420A5 (cg-RX-API-DMAC7.html)
JP2021528047A5 (cg-RX-API-DMAC7.html)
JP2010532169A5 (cg-RX-API-DMAC7.html)
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
HRP20150256T1 (hr) Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe
JP2022526841A5 (cg-RX-API-DMAC7.html)
CN114181310A (zh) 抗tigit抗体、其药物组合物及用途
JP2024521472A5 (cg-RX-API-DMAC7.html)
US20250215087A1 (en) Combination therapy of kras inhibitor and treg depleting agent
KR20240039006A (ko) 신규 항-sirpa 항체
CA3208473A1 (en) Pharmaceutical composition and use thereof
JP7663265B2 (ja) 抗SIRPα抗体またはその抗原結合断片および適用
CN112969715B (zh) 一种抗cd47抗原结合蛋白及其应用
AU2019306113B2 (en) Anti-human PD-L1 antibodies and their uses